PRTN3 and rheumatoid arthritis: In 2010, the ACR and EULAR added anti-CCP Ab, also known as ACPA, a biomarker predicting aggressive RA, to the existing biomarker, RF, and revised the classification criteria to emphasize the characteristics of early RA49.